Evicenter
P&T meetings

LB-102

Schizophrenia

Regulatory submission
Not announced
Launch
Not announced
Last updated
345 sources

Product information and disease descriptionProduct descriptionProduct information

American hospital formulary service (AHFS), or other drug classification

2 evidence topics · 3 sources

Mechanistic and chemical classification

“LB-102 is a dopamine D2/3 and 5HT7 antagonist.” (opens the source at this quote in a new tab)

“We believe an effective LAI form of LB-102 has the potential to benefit patients worldwide, as relatively few approved agents are available as long-acting formulations and there are no benzamide class LAIs currently available or in development worldwide.” (opens the source at this quote in a new tab)

Anatomical Therapeutic Chemical classification of the parent compound amisulpride
ATC levelQuoted record
N05A“ANTIPSYCHOTICS”
N05AL“Benzamides”
N05AL05“amisulpride”
AHFS Pharmacologic-Therapeutic Classification and ATC code assigned to LB-102

No evidence found.